NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Attorney Advertising
-- Bronstein, Gewirtz & Grossman, LLC is investigating
potential claims on behalf of purchasers of the securities of
Fresenius Medical Care AG & Co. KGAA ("Fresenius" or the
"Company") (NYSE: FMS). Such investors can obtain additional
information and assist the investigation by visiting the firm's
site: www.bgandg.com/fms.
The investigation concerns whether Fresenius and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On January 7, 2017, Fresenius
revealed that its U.S. unit had received subpoenas from federal
prosecutors asking for information about its connection with the
American Kidney Fund, a charity that assists patients pay for
kidney dialysis. Following this news, Fresenius stock has
dropped as much as $3.09 per share,
or 7.26%, to $39.46 on January 9, 2017.
If you are aware of any facts relating to this investigation, or
purchased Fresenius shares, you can assist this investigation by
visiting the firm's site: www.bgandg.com/fms. You can
also contact Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-fresenius-medical-care-ag--co-kgaa-fms-300387926.html
SOURCE Bronstein, Gewirtz & Grossman, LLC